The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for SL1009 (sodium dichloroacetate oral solution) for the treatment of pyruvate dehydrogenase complex ...
FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial ROSWELL, ...
CWRU has a decades-long history of research into pyruvate dehydrogenase complex deficiency (PDCD). The pyruvate dehydrogenase complex (PDC) is a multiple enzyme complex in the shape of a pentagonal ...
Pyruvate dehydrogenase complex deficiency (PDCD) (formerly known as PDH deficiency) is an inherited inborn error of metabolism. This means that children born with ...
The Company is currently seeking a path forward with the FDA that would not require an additional clinical trial. The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to ...
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Sept. 8, 2025 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug ...
March 18, 2024 – Cure Mito Foundation and Hope for PDCD foundation, both patient-led foundations focused on advancing research and supporting families affected by Leigh syndrome and Pyruvate ...
This week’s Capitol Hill meetings come on the heels of rejections of ultra-rare disease drugs developed by Biohaven and Saol Therapeutics. Physicians and patient groups implored the FDA to expedite ...
GRAND RAPIDS, Mich. — A West Michigan family is spreading the word about their daughter's rare diagnosis in the hopes of funding research about Pyruvate Dehydrogenase Complex Deficiency (PDCD). Andrew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results